RVMD
Revolution Medicines
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
- Revolution Medicines Receives FDA Orphan Drug Designation for Daraxonrasib in Pancreatic CancerOct 27, 2025
- Revolution Medicines Announces FDA Breakthrough Therapy Designation for ElironrasibJul 23, 2025
- Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 MutationsJun 24, 2025
News
- Revolution Medicines' RASONQUE (daraxonrasib) receives a positive CHMP opinion recommending marketing authorization in the EU for metastatic pancreatic cancerOct 15, 2026
- FDA granted Breakthrough Therapy Designation to RASONQUE for first-line metastatic pancreatic cancer when combined with chemotherapySep 15, 2026
- Newly approved Rasonque showed a 42% overall response rate and 16-month overall survival in a relevant subgroup of patients with RAS-mutant non-small cell lung cancerSep 7, 2026
- Newly approved Rasonque showed a 42% overall response rate and 16-month overall survival in a relevant subgroup of patients with RAS-mutant non-small cell lung cancerSep 7, 2026
- The New England Journal of Medicine published Phase 1/2 clinical data for Revolution Medicines' RASONQUE in metastatic non-small cell lung cancerSep 7, 2026